Search results for "sequencing"

showing 10 items of 1087 documents

Functional analysis of TLK2 variants and their proximal interactomes implicates impaired kinase activity and chromatin maintenance defects in their p…

2020

IntroductionThe Tousled-like kinases 1 and 2 (TLK1 and TLK2) are involved in many fundamental processes, including DNA replication, cell cycle checkpoint recovery and chromatin remodelling. Mutations in TLK2 were recently associated with ‘Mental Retardation Autosomal Dominant 57’ (MRD57, MIM# 618050), a neurodevelopmental disorder characterised by a highly variable phenotype, including mild-to-moderate intellectual disability, behavioural abnormalities, facial dysmorphisms, microcephaly, epilepsy and skeletal anomalies.MethodsWe re-evaluate whole exome sequencing and array-CGH data from a large cohort of patients affected by neurodevelopmental disorders. Using spatial proteomics (BioID) and…

0301 basic medicineNeurobiologia del desenvolupamentMicrocephalymissenseMolecular biologyBiologymedicine.disease_causemedicalloss of function mutation03 medical and health sciencesmutation.0302 clinical medicineNeurodevelopmental disordermedicineChromatin maintenanceMissense mutationmolecular biologygeneticsDevelopmental neurobiologyKinase activitygenetic research; genetics; loss of function mutation; medical; missense; molecular biology; mutationGenetics (clinical)Exome sequencingBiologia molecularGeneticsMutationgenetic researchmedicine.diseaseChromatin030104 developmental biologymutationgenetic030217 neurology & neurosurgery
researchProduct

Subtracting the sequence bias from partially digested MNase-seq data reveals a general contribution of TFIIS to nucleosome positioning.

2017

Background TFIIS stimulates RNA cleavage by RNA polymerase II and promotes the resolution of backtracking events. TFIIS acts in the chromatin context, but its contribution to the chromatin landscape has not yet been investigated. Co-transcriptional chromatin alterations include subtle changes in nucleosome positioning, like those expected to be elicited by TFIIS, which are elusive to detect. The most popular method to map nucleosomes involves intensive chromatin digestion by micrococcal nuclease (MNase). Maps based on these exhaustively digested samples miss any MNase-sensitive nucleosomes caused by transcription. In contrast, partial digestion approaches preserve such nucleosomes, but intr…

0301 basic medicineNucleosome mappinglcsh:QH426-470MNase-sensitive nucleosomesRNA polymerase IIComputational biologySaccharomyces cerevisiaeReal-Time Polymerase Chain ReactionBiotecnologia03 medical and health sciencesTranscription (biology)Gene expressionGeneticsNucleosomeMNase-seqMicrococcal NucleaseMolecular BiologyGenebiologyMethodologyHigh-Throughput Nucleotide SequencingPromoterChromatinNucleosomeslcsh:Genetics030104 developmental biologyNucleosomal fuzzinessSubtraction TechniqueTFIISbiology.proteinTranscriptional Elongation FactorsGenèticaMicrococcal nuclease
researchProduct

Improving the Management of Patients with Hearing Loss by the Implementation of an NGS Panel in Clinical Practice

2020

A cohort of 128 patients from 118 families diagnosed with non-syndromic or syndromic hearing loss (HL) underwent an exhaustive clinical evaluation. Molecular analysis was performed using targeted next-generation sequencing (NGS) with a custom panel that included 59 genes associated with non-syndromic HL or syndromic HL. Variants were prioritized according to the minimum allele frequency and classified according to the American College of Medical Genetics and Genomics guidelines. Variant(s) responsible for the disease were detected in a 40% of families including autosomal recessive (AR), autosomal dominant (AD) and X-linked patterns of inheritance. We identified pathogenic or likely pathogen…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyAdolescentlcsh:QH426-470Hearing lossHearing Loss Sensorineuralclinical evaluationPopulationGenomicsDiseaseDeafnessArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansgeneticsmolecular analysiseducationChildAllele frequencyGenetics (clinical)hearing losseducation.field_of_studybusiness.industryInfant NewbornHigh-Throughput Nucleotide SequencingInfantMiddle Agedmedicine.diseaselcsh:Genetics030104 developmental biologyChild PreschoolCohortMedical geneticsSensorineural hearing lossFemalenext-generation sequencingmedicine.symptombusiness030217 neurology & neurosurgeryGenes
researchProduct

Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas

2021

Background: Bone and soft-tissue sarcomas represent 13% of all paediatric malignancies. International contributions to introduce next-generation sequencing (NGS) approaches into clinical application are currently developing. We present the results from the Precision Medicine program for children with sarcomas at a reference centre. Results: Samples of 70 paediatric sarcomas were processed for histopathological analysis, reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS) with a consensus gene panel. Pathogenic alterations were reported and, if existing, targeted recommendations were translated to the clinic. Seventy paediatric patients with sarcomas…

0301 basic medicineOncologyCàncer en els infantsmedicine.medical_specialtyprecision medicinetargeted drugslcsh:MedicineMedicine (miscellaneous)Articlepaediatric sarcomasclinical translationDNA sequencinglaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineGene panelmedicineOssos MalaltiesPolymerase chain reactionPaediatric patientsBiological studiesbusiness.industrylcsh:RHistopathological analysisPrecision medicine030104 developmental biology030220 oncology & carcinogenesisCohortnext-generation sequencingbusinessJournal of Personalized Medicine
researchProduct

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhib…

2019

[Objectives] Resistance to tyrosine-kinase inhibitors (TKIs) is a clinical challenge in patients with oncogene-driven non-small-cell lung cancers (NSCLC). We have analyzed the utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) to impact the clinical care of patients with TKI resistance.

0301 basic medicineOncologyMaleCancer ResearchLung NeoplasmsTyrosine-kinase inhibitorCirculating Tumor DNAchemistry.chemical_compound0302 clinical medicineCarcinoma Non-Small-Cell LungMedicineOsimertinibNeoplasm MetastasisProspective cohort studyAged 80 and overDisease ManagementHigh-Throughput Nucleotide SequencingMiddle AgedOncology030220 oncology & carcinogenesisFemalemedicine.drugPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyCabozantinibmedicine.drug_class03 medical and health sciencesInternal medicineROS1Biomarkers TumorHumansLung cancerProtein Kinase InhibitorsAgedNeoplasm StagingDigital next-generation sequencingTKI resistanceCrizotinibbusiness.industryOncogene-driven NSCLCOncogenesctDNAmedicine.diseaseLorlatinibrespiratory tract diseases030104 developmental biologychemistryDrug Resistance NeoplasmMutationbusinessOsimertinib
researchProduct

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing : results of the RING observational trial

2020

Plasma samples from 72 EGFR‐mutant advanced NSCLC patients, collected upon progression to first‐line TKI, were analyzed by seven methodologies (two NGS‐based methods, three high‐sensitivity PCR‐based platforms, and two FDA‐approved methods). Our study demonstrates a good to excellent agreement between methodologies and supports the use of liquid biopsies for therapy decision‐making.

0301 basic medicineOncologyMaleCancer Researchcell lung cancerIntraclass correlationBiopsyDNA Mutational Analysisnon-small cell lung cancer (NSCLC)Tyrosine kinase inhibitorTyrosine-kinase inhibitorCohort Studies*circulating free DNAT790M0302 clinical medicinetyrosine kinase inhibitorGene FrequencyOsimertinibProspective cohort studyCàncernon‐small‐cell lung cancerCirculating free DNARC254-282Research ArticlesSequence DeletionAged 80 and overNeoplasms. Tumors. Oncology. Including cancer and carcinogensHigh-Throughput Nucleotide Sequencingnon&#8208General MedicineDNA NeoplasmExonsMiddle AgedErbB ReceptorsEpidermal growth factor receptor (EGFR) NGS Non-small cell lung cancer (NSCLC) PCR Tyrosine Kinase Inhibitor (TKI) circulating free DNA (cfDNA) osimertinibOncology030220 oncology & carcinogenesisosimertinibNGSMolecular Medicinesmall&#8208FemaleResearch Article*NGSAdultmedicine.medical_specialtymedicine.drug_classSensitivity and Specificity03 medical and health sciencesPredictive Value of TestsInternal medicineGeneticsmedicineHumansAged*non-small-cell lung cancerbusiness.industryEpidermal growth factor receptorNon invasive*epidermal growth factor receptormedicine.disease*tyrosine kinase inhibitorrespiratory tract diseases030104 developmental biologyEgfr mutationPulmonsMutationcirculating free DNAbusinessepidermal growth factor receptorNon-small-cell lung cancer*osimertinibOsimertinib
researchProduct

Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy

2019

[EN] Somatic mutation analysis and evaluation of microsatellite instability (MSI) have become mandatory for selecting personalized therapy strategies for advanced colorectal cancer and are not available as routine methods in Paraguay. The aims of this study were to analyze the molecular profile as well as the microsatellite status in a series of advanced colorectal patients from two public hospitals from Paraguay, to introduce these methodologies in the routine practice to guide the therapeutic decisions. Thirty-six patients diagnosed with advanced colorectal cancer from two referent public hospitals from Paraguay were recruited from May 2017 to February 2018. Sequenom Mass spectrometry, On…

0301 basic medicineOncologyMaleCancer Researchmutational profileColorectal cancerDNA Mutational AnalysisKaplan-Meier Estimate0302 clinical medicineOriginal ResearchCancer BiologyPrecision medicineHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisImmunohistochemistryOncology030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityDisease SusceptibilityColorectal NeoplasmsAdultmedicine.medical_specialtyprecision medicinecolorectal cancerlcsh:RC254-28203 medical and health sciencesYoung AdultInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingAgedNeoplasm Stagingbusiness.industryMicrosatellite instabilityOncocartaPrecision medicinemedicine.diseaseColorectal cancerMutational profile030104 developmental biologyMutationMicrosatellite instabilityMolecular ProfileNeoplasm GradingbusinessLENGUAJES Y SISTEMAS INFORMATICOSMicrosatellite Repeats
researchProduct

A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for…

2020

AIMS Studies in various cancer types have demonstrated discordance between results from different programmed death-ligand 1 (PD-L1) assays. Here, we compare the reproducibility and analytical concordance of four clinically developed assays for assessing PD-L1-positivity in tumour-infiltrating immune cells in the tumour area (PD-L1-IC-positivity) in triple-negative breast cancer (TNBC). METHODS AND RESULTS Primary TNBC resection specimens (n = 30) were selected based on their PD-L1-IC-positivity per VENTANA SP142 ( 5%: eight cases). Serial histological sections were stained for PD-L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3 and DAKO 28-8. PD-L1-IC-positivity and tumour cell expression (…

0301 basic medicineOncologyMalemedicine.medical_specialtyHistologyConcordanceTriple Negative Breast NeoplasmsB7-H1 AntigenPathology and Forensic MedicineCohort Studies03 medical and health sciences0302 clinical medicineBreast cancerLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorHumansTriple-negative breast cancerAgedReproducibilityWhole Genome Sequencingbusiness.industryCancerHigh-Throughput Nucleotide SequencingReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryddc:030104 developmental biology030220 oncology & carcinogenesisMutationComparison studyImmunohistochemistryFemaleNeoplasm GradingbusinessProgrammed deathHistopathologyReferences
researchProduct

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.

2019

A high percentage of patients diagnosed with localized colon cancer (CC) will relapse after curative treatment. Although pathological staging currently guides our treatment decisions, there are no biomarkers determining minimal residual disease (MRD) and patients are at risk of being undertreated or even overtreated with chemotherapy in this setting. Circulating-tumor DNA (ctDNA) can to be a useful tool to better detect risk of relapse.One hundred and fifty patients diagnosed with localized CC were prospectively enrolled in our study. Tumor tissue from those patients was sequenced by a custom-targeted next-generation sequencing (NGS) panel to characterize somatic mutations. A minimum varian…

0301 basic medicineOncologyMalemedicine.medical_specialtyNeoplasm ResidualColorectal cancerColonmedicine.medical_treatmentPathological stagingConcordanceDNA Mutational AnalysisKaplan-Meier EstimateAdenocarcinomaDisease-Free Survivallaw.inventionCirculating Tumor DNA03 medical and health sciences0302 clinical medicineGene FrequencylawInternal medicineBiomarkers TumorMedicineHumansDigital polymerase chain reactionPostoperative PeriodProspective StudiesPolymerase chain reactionColectomyAgedChemotherapybusiness.industryHazard ratioHigh-Throughput Nucleotide SequencingHematologymedicine.diseaseMinimal residual disease030104 developmental biologyOncology030220 oncology & carcinogenesisColonic NeoplasmsMutationFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families

2021

(1) Background: Over the last decade, genetic counseling clinics have moved from single-gene sequencing to multigene panel sequencing. Multiple genes related to a moderate risk of breast cancer (BC) have emerged, although many questions remain regarding the risks and clinical features associated with these genes. (2) Methods: Ninety-six BC index cases (ICs) with high-risk features for hereditary breast and ovarian cancer (HBOC) and with a previous uninformative result for BRCA1/2 were tested with a panel of 41 genes associated with BC risk. The frequency of pathogenic variants (PVs) was related to the clinical characteristics of BC. (3) Results: We detected a PV rate of 13.5% (excluding two…

0301 basic medicineOncologymedicine.medical_specialtyCandidate geneGenetic counselingMedicine (miscellaneous)germline testingmoderate penetrance geneshereditary breast and ovarian cancerArticle03 medical and health sciences0302 clinical medicineBreast cancerMUTYHInternal medicinemedicineCHEK2BRCA1 or BRCA2 negativebusiness.industryRBRIP1medicine.disease030104 developmental biologyMSH2030220 oncology & carcinogenesisCohortMedicinenext-generation sequencingbusinessJournal of Personalized Medicine
researchProduct